Exa-cel (exagamglogene autotemcel) is a one-time gene-editing therapy for severe sickle cell disease and transfusion-dependent beta-thalassemia, marketed as Casgevy. It uses CRISPR-Cas9 to edit a patient’s own blood stem cells so they make large amounts of fetal hemoglobin, which compensates for the faulty adult hemoglobin. It was the first CRISPR-based medicine approved for use in patients, starting in late 2023 for people aged 12 and older. It offers the possibility of a lasting remission without a donor, but it requires intensive chemotherapy and a long hospital stay.
The Blood Disorders Exa-cel Targets
Sickle cell disease and beta-thalassemia are inherited blood disorders caused by mutations in the beta-globin gene (HBB). Adult hemoglobin (HbA) is made of two alpha and two beta chains, so a faulty beta chain affects every red cell.
- In sickle cell disease, abnormal hemoglobin S polymerizes when oxygen is low. This makes red cells rigid and sickle-shaped. They block small vessels, causing painful vaso-occlusive crises, strokes, and organ damage.
- In beta-thalassemia, too little beta chain is made. Red cells are produced inefficiently, and severe forms need regular transfusions for life, which leads to iron overload.
Both conditions affect all blood cells indirectly through chronic anemia, inflammation, and marrow stress. That makes them some of the most burdensome blood disorders for patients and families.
How Exa-cel Works
Exa-cel does not repair the beta-globin mutation. Instead, it switches back on a hemoglobin the body already knows how to make. Before birth, we all produce fetal hemoglobin (HbF), which uses gamma chains instead of beta chains. Shortly after birth, a protein called BCL11A shuts gamma-globin production down.
Exa-cel uses CRISPR-Cas9 to cut a specific erythroid enhancer of the BCL11A gene. This lowers BCL11A only in developing red cells, so they resume making fetal hemoglobin. HbF does not sickle and can stand in for the missing beta chains in thalassemia.
This approach was inspired by a natural observation. People with sickle cell or thalassemia genes who also inherit hereditary persistence of fetal hemoglobin tend to have much milder disease. Hydroxyurea, a long-standing sickle cell drug, works partly by raising HbF too, though to a much smaller degree.
| Feature | Exa-cel | Donor (allogeneic) stem cell transplant |
|---|---|---|
| Source of cells | Patient’s own edited stem cells | Matched sibling or other donor |
| Donor needed | No | Yes; many patients lack a matched sibling |
| Graft-versus-host disease risk | None, because the cells are the patient’s own | Present |
| Immunosuppression after treatment | Not required | Usually required for months |
| Chemotherapy conditioning | Myeloablative busulfan | Required; intensity varies |
The Treatment Journey, Step by Step
- Evaluation: A hematological work-up checks heart, lung, liver, and kidney function. It also includes fertility counseling and psychosocial assessment.
- Preparation: Sickle cell patients usually receive red cell transfusions for a period beforehand to lower hemoglobin S and reduce crisis risk.
- Stem cell mobilization and collection: Plerixafor is used to release stem cells into the blood, and they are collected by apheresis. G-CSF is avoided in sickle cell disease because it can trigger crises. Several collection cycles may be needed.
- Manufacturing: The cells are edited and quality-tested in a specialized laboratory. This takes several months.
- Conditioning: The patient is admitted for myeloablative busulfan, which clears the existing marrow to make room for the edited cells.
- Infusion and engraftment: The edited cells are infused through a vein. The patient then stays in hospital, often for a month or more, until neutrophils and platelets recover.
Risks and Side Effects
Most serious side effects come from the busulfan conditioning, not from the gene edit itself.
- Prolonged low blood counts: Low counts after conditioning bring risks of infection and bleeding. They require transfusions and careful monitoring until engraftment.
- Mouth sores, nausea, and hair loss during the conditioning period
- Infertility: Busulfan frequently damages fertility, so egg, sperm, or tissue preservation should be discussed before treatment.
- Liver toxicity: Including veno-occlusive disease, a known busulfan complication
- Long-term unknowns: Off-target CRISPR edits are a theoretical concern. Patients are enrolled in long-term follow-up to watch for delayed effects.
Because the cells are the patient’s own, graft-versus-host disease is not expected. This is one of the clearest differences from donor transplant.
Life After Discharge
Recovery continues well after the patient leaves hospital. Blood counts are checked frequently at first, and the immune system takes months to rebuild. During that time patients take infection precautions and, in time, repeat their childhood vaccinations. Fetal hemoglobin levels are tracked to confirm the edited cells are working. Patients with thalassemia may still need treatment to remove iron that built up from years of transfusions.
Who Is a Candidate?
Exa-cel is currently approved for people aged 12 and over with sickle cell disease and recurrent vaso-occlusive crises, or with transfusion-dependent beta-thalassemia. Suitable candidates must be well enough to tolerate myeloablative chemotherapy.
In my practice, the decision is rarely about eligibility alone. It rests on a frank discussion of disease burden versus the demands of treatment: months of preparation, a long admission, and likely loss of fertility. Access, cost, and the limited number of treatment centers are also real practical barriers. Families benefit from genetic counseling as part of understanding genetic blood disorders more broadly, including what the diagnosis means for siblings and future children.
Key Takeaways
- Exa-cel edits a patient’s own stem cells to restore fetal hemoglobin rather than fixing the beta-globin mutation.
- In the clinical trials, most treated patients became free of severe vaso-occlusive crises or no longer needed regular transfusions.
- The main risks come from busulfan conditioning, including infertility and prolonged low blood counts.
- Long-term follow-up is essential because the therapy is still new.
Frequently Asked Questions
Is exa-cel a cure for sickle cell disease?
It can produce a lasting, disease-free state in many patients, and some clinicians describe it as potentially curative. However, the edited cells still carry the sickle mutation, and long-term durability is still being studied. It is more accurate to call it a one-time treatment with the potential to be curative.
How is exa-cel different from a bone marrow transplant?
It uses the patient’s own cells, so no donor is needed and there is no graft-versus-host disease. It still requires the same kind of high-dose chemotherapy conditioning as a transplant.
Will my children inherit the edit?
No. The edit is made only in blood stem cells, not in eggs or sperm. Children can still inherit the original sickle cell or thalassemia gene.
How long does the whole process take?
From the first evaluation to recovery after infusion, it typically takes many months, and often close to a year. Manufacturing and multiple collection cycles are the usual reasons it takes so long.
For background on the disease itself, see our sickle cell guide.
